Roche has announced the FDA approval of its self-sampling solution for human papillomavirus (HPV).

This solution will enable individuals to collect a vaginal sample themselves for HPV screening, which will then be analyzed in the laboratory using Roche's cobas molecular instrument.

This tool facilitates access to HPV screening, reducing barriers such as access to healthcare, social and economic barriers, trauma history, cultural concerns and embarrassment.

This development supports the WHO's goal of eliminating cervical cancer by 2030 by improving screening rates

Copyright (c) 2024 CercleFinance.com. All rights reserved.